| NCT ID | NCT03845946 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | ANGIOEDEMA |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2018-09-01 |
| Primary Completion | 2028-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2018-09-01 with a primary completion date of 2028-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Angioedema is a disease characterized by the appearance of self-limiting edema that last 1-5 days and affect the subcutaneous tissue and/or gastrointestinal and oropharyngeal mucosa. In this last location edema can be lethal causing asphyxia, in all other cases full recovery is complete. Attacks can appear as part of the syndrome urticaria angioedema and can be of allergic origin. But there is a group of non-allergic angioedema that occur without hives and can be either hereditary or acquired. These angioedema are identified in some cases on the basis of etiology, in others are identified by the mediator and an overall classification of these forms of angioedema was published in 2014 as a result of a consent conference organized by the proponents of this registry. Being these forms of angioedema rare, there are not significative case studies inclusive of a high number of patients. This registry aims to collect in a single place a high number of subjects with recurring angioedema and without urticaria.
Eligibility Criteria
Inclusion Criteria: * Any patient with isolated angioedema without associated wheals. * Patients with hereditary angioedema with or without C1 deficiency. * Major patient with consent (signature) * Minor patient whose parents / legal guardians have given their consent (signature) Exclusion Criteria: * Patient unable to give consent. * Wheals with angioedema
Contact & Investigator
laurence bouillet
PRINCIPAL INVESTIGATOR
University Hospital, Grenoble
Frequently Asked Questions
Who can join the NCT03845946 clinical trial?
This trial is open to participants of all sexes, studying ANGIOEDEMA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03845946 currently recruiting?
Yes, NCT03845946 is actively recruiting participants. Contact the research team at lbouillet@chu-grenoble.fr for enrollment information.
Where is the NCT03845946 trial being conducted?
This trial is being conducted at Grenoble, France.
Who is sponsoring the NCT03845946 clinical trial?
NCT03845946 is sponsored by University Hospital, Grenoble. The principal investigator is laurence bouillet at University Hospital, Grenoble. The trial plans to enroll 1,000 participants.